Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $515

Benzinga · 3d ago
Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $460 to $515.